Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 08, 2024

SELL
$525.19 - $619.13 $525 - $619
-1 Reduced 0.22%
450 $262,000
Q3 2023

Oct 13, 2023

BUY
$434.7 - $599.3 $434 - $599
1 Added 0.22%
451 $242,000
Q1 2023

May 03, 2023

SELL
$310.63 - $364.82 $931 - $1,094
-3 Reduced 0.66%
450 $154,000
Q4 2022

Jan 05, 2023

SELL
$321.55 - $374.67 $144,697 - $168,601
-450 Reduced 49.83%
453 $0
Q3 2022

Oct 24, 2022

BUY
$296.48 - $337.87 $889 - $1,013
3 Added 0.33%
903 $292,000
Q1 2022

Apr 08, 2022

SELL
$234.69 - $291.66 $93,876 - $116,664
-400 Reduced 30.77%
900 $258,000
Q3 2021

Oct 22, 2021

SELL
$221.6 - $272.71 $182,820 - $224,985
-825 Reduced 38.82%
1,300 $300,000
Q2 2021

Aug 02, 2021

SELL
$180.55 - $233.54 $212,146 - $274,409
-1,175 Reduced 35.61%
2,125 $488,000
Q4 2020

Jan 21, 2021

SELL
$130.46 - $172.63 $107,629 - $142,419
-825 Reduced 20.0%
3,300 $557,000
Q3 2020

Oct 06, 2020

SELL
$146.22 - $169.13 $120,631 - $139,532
-825 Reduced 16.67%
4,125 $611,000
Q2 2020

Jul 16, 2020

BUY
$136.42 - $164.18 $36,560 - $44,000
268 Added 5.72%
4,950 $813,000
Q1 2020

Apr 21, 2020

SELL
$119.05 - $147.35 $152,145 - $188,313
-1,278 Reduced 21.44%
4,682 $649,000
Q4 2019

Jan 22, 2020

SELL
$106.92 - $132.43 $10,692 - $13,243
-100 Reduced 1.65%
5,960 $783,000
Q3 2019

Oct 17, 2019

SELL
$106.79 - $116.16 $10,679 - $11,616
-100 Reduced 1.62%
6,060 $678,000
Q2 2019

Jul 29, 2019

SELL
$110.79 - $129.32 $6,647 - $7,759
-60 Reduced 0.96%
6,160 $682,000
Q1 2019

May 03, 2019

SELL
$111.31 - $131.02 $99,065 - $116,607
-890 Reduced 12.52%
6,220 $807,000
Q4 2018

Feb 04, 2019

SELL
$105.9 - $118.64 $5,295 - $5,932
-50 Reduced 0.7%
7,110 $823,000
Q1 2018

May 09, 2018

SELL
$74.21 - $87.6 $29,683 - $35,040
-400 Reduced 5.29%
7,160 $554,000
Q3 2017

Nov 21, 2017

SELL
$77.07 - $85.54 $12,793 - $14,199
-166 Reduced 2.15%
7,560 $647,000
Q2 2017

Aug 14, 2017

BUY
N/A
7,726
7,726 $636,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $864B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Optimum Investment Advisors Portfolio

Follow Optimum Investment Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Optimum Investment Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Optimum Investment Advisors with notifications on news.